Novel KIF18A inhibitor, ATX-295, shows enriched activity in ovarian and TNBC preclinical models with whole genome doubling First-in-class DHX9 inhibitor, ATX-559, demonstrates potent activity in preclinical models of MSI-H and BRCA-deficient cancers Both ATX-295 and ATX-559 programs are…